SCHEMBL800679

SCHEMBL800679

CC(C)C(=O)CCCCN

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAOX Q6QHF9 4/20 0.52
CYP2D6 P10635 1/20 0.50
NFKB1 P19838 1/20 0.50
BLM P54132 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
LMNA P02545 2/20 0.48
THRB P10828 2/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
PLG P00747 1/20 0.48
ALOX15 P16050 1/20 0.48
SLC6A2 P23975 1/20 0.48
RECQL P46063 1/20 0.48
SLC6A3 Q01959 1/20 0.48
LTA4H P09960 1/20 0.41
GABRR1 P24046 3/20 0.40
CYP1A2 P05177 2/20 0.40
GABRR3 A8MPY1 1/20 0.40
GABRP O00591 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13300751 0.98 PAOX (0.56) PAOXCYP2D6NFKB1BLMNPSR1
SCHEMBL27050934 0.98 PAOX (0.56) PAOXCYP2D6NFKB1BLMNPSR1
SCHEMBL260557 0.98 PAOX (0.56) PAOXCYP2D6NFKB1BLMNPSR1
SCHEMBL26019316 0.98 PAOX (0.56) PAOXCYP2D6NFKB1BLMNPSR1
SCHEMBL800654 0.92
SCHEMBL17992598 0.87 CES2 (0.44) LMNAKMT2AMEN1LTA4HCES2
SCHEMBL21501562 0.86 PAOX (0.45) PAOXCYP2D6NFKB1BLMNPSR1
SCHEMBL9973392 0.84 CES2 (0.48) NFKB1LMNAKMT2AMEN1LTA4H
SCHEMBL9973396 0.84 CES2 (0.48) NFKB1LMNAKMT2AMEN1LTA4H
SCHEMBL18751717 0.84 CES2 (0.48) NFKB1LMNAKMT2AMEN1LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11786547-B2 Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds SYNEDGEN, INC. (US) 2023-10-17 US disclosed
US-11786547-B2 Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds SYNEDGEN, INC. (US) 2023-10-17 US disclosed
US-11717532-B2 Methods and compositions for treating wounds utilizing chitosan compounds SYNEDGEN, INC. (US) 2023-08-08 US disclosed
US-11717532-B2 Methods and compositions for treating wounds utilizing chitosan compounds SYNEDGEN, INC. (US) 2023-08-08 US disclosed
US-20230201248-A1 COMPOSITIONS AND METHODS OF USE THEREOF SYNEDGEN, INC. 2023-06-29 US disclosed
US-20230201248-A1 COMPOSITIONS AND METHODS OF USE THEREOF SYNEDGEN, INC. 2023-06-29 US disclosed
US-20230181623-A1 COMPOSITIONS AND METHODS OF USE FOR WOUND HEALING SYNEDGEN, INC. 2023-06-15 US disclosed
EP-2968080-B1 ORAL FORMULATION OF POLYGLUCOSAMINE DERIVATIVES IN COMBINATION WITH A NON-FERMENTABLE SUGAR SYNEDGEN INC (US) 2023-05-10 EP disclosed
US-11433092-B2 Compositions and methods of use for wound healing SYNEDGEN, INC. (US) 2022-09-06 US disclosed
US-20210386774-A1 METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION, TRAUMA OR SHOCK SYNEDGEN, INC. 2021-12-16 US disclosed
US-20120070370-A1 SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS MERCK SHARP & DOHME CORP. 2012-03-22 US disclosed
US-20120046291-A1 Extended Triterpene Derivatives MYREXIS, INC. 2012-02-23 US disclosed
US-20110171172-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY MERCK SHARP & DOHME CORP. 2011-07-14 US disclosed
US-20110171172-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY MERCK SHARP & DOHME CORP. 2011-07-14 US disclosed
US-20110150757-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY MERCK SHARP & DOHME CORP. 2011-06-23 US disclosed
US-20110123435-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY MERCK SHARP & DOHME LLC 2011-05-26 US disclosed
WO-2011028967-A1 METHODS AND COMPOSITIONS FOR DISRUPTING BIOFILM UTILIZING CHITOSAN-DERIVATIVE COMPOUNDS SYNEDGEN INC. (US) 2011-03-10 WO disclosed
US-20100137193-A1 CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH SYNEDGEN INC. (US) 2010-06-03 US disclosed
US-20100130443-A1 CHITOSAN DERIVATIVES, COMPOSITIONS AND RELATED METHODS OF USE SYNEDGEN INC. (US) 2010-05-27 US disclosed
US-20100056474-A1 Methods and Compositions for the Prevention of and Treatment of Infections Utilizing Chitosan-Derivative Compounds UNITED STATES GOVERNMENT 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11433092-B2 Compositions and methods of use for wound healing PARG, ARGLU1, AREG PAOX 1447/4885CYP2D6 4856/4885NFKB1 915/4885
US-20110150757-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY KIF18B, KIF5B, KIF18A PAOX 3555/4885CYP2D6 4517/4885NFKB1 2141/4885
US-20120070370-A1 SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS KIF2C, SKP1, KIF5B PAOX 3200/4885CYP2D6 4281/4885NFKB1 2214/4885
US-20230181623-A1 COMPOSITIONS AND METHODS OF USE FOR WOUND HEALING PARG, ARGLU1, AREG PAOX 1447/4885CYP2D6 4856/4885NFKB1 915/4885
US-20210386774-A1 METHODS FOR TREATMENT OR PREVENTION OF DAMAGE RESULTING FROM RADIATION, TRAUMA OR SHOCK HMGB1, ELANE, SERPINB1 PAOX 2674/4885CYP2D6 4038/4885NFKB1 174/4885
US-20100137193-A1 CHITOSAN DERIVATIVES TO TREAT ANIMALS OR OPTIMIZE ANIMAL HEALTH CHIT1, CHIA, ALG1 PAOX 2415/4885CYP2D6 4236/4885NFKB1 627/4885
US-20110123435-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY KIF5B, KIF2C, KIFC1 PAOX 3234/4885CYP2D6 4566/4885NFKB1 2052/4885
US-20100056474-A1 Methods and Compositions for the Prevention of and Treatment of Infections Utilizing Chitosan-Derivative Compounds NRDC, ARG1, CHIA PAOX 4010/4885CYP2D6 3218/4885NFKB1 1630/4885
US-20120046291-A1 Extended Triterpene Derivatives BET1, PGGT1B, TMPO PAOX 1609/4885CYP2D6 417/4885NFKB1 860/4885
US-20110171172-A1 COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY KIF5B, KIF2C, KIFC1 PAOX 3535/4885CYP2D6 4580/4885NFKB1 1779/4885
US-11717532-B2 Methods and compositions for treating wounds utilizing chitosan compounds CHIA, MMP8, CHIT1 PAOX 2479/4885CYP2D6 4572/4885NFKB1 1791/4885
US-20230201248-A1 COMPOSITIONS AND METHODS OF USE THEREOF ENGASE, FUT5, ALG1 PAOX 585/4885CYP2D6 3041/4885NFKB1 3142/4885
US-11786547-B2 Methods and compositions for disrupting biofilm utilizing chitosan-derivative compounds CHIT1, ALG1, CSGALNACT1 PAOX 3756/4885CYP2D6 4313/4885NFKB1 3153/4885
US-20100130443-A1 CHITOSAN DERIVATIVES, COMPOSITIONS AND RELATED METHODS OF USE CHIT1, CHIA, ALG1 PAOX 3569/4885CYP2D6 2557/4885NFKB1 2681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.